On January 29, the European Medicines Agency (EMA) held a joint press conference with members of the Dutch government to unveil plans for the new customized headquarters facility being built in the Zuidas business district.
On January 29, the European Medicines Agency (EMA) held a joint press conference with members of the Dutch government to unveil plans for the new, customized headquarters facility being built in the Zuidas business district.
Bruno Bruins, minister for medical care in The Netherlands, took the stage to announce that, due to the tight timeline of the move—the EMA needs to be up and running by March 1, 2019 in Amsterdam—the agency will be able to utilize the temporary headquarters as soon as January 1, 2019.
“We are fully committed to making your relocation as smooth as possible, to provide you with all the help and advice you seek to settle down. We are working hard to find houses for you and your families, schools for your children, and other facilities you may need, and we are almost ready to receive you and your loved ones,” said Bruins.
The executive director of EMA, Guido Rasi, MD, commended Amsterdam for its willingness to engage in negotiations with EMA staff as they look to preserve the work that benefits “500 million cities in Europe and protect public health.” Rasi also underscored the fact that, in a staff survey last year, 81% of EMA’s 900 workers said they would move to Amsterdam if the city were selected for the agency’s new home after it leaves London, United Kingdom, as a result of the nation’s Brexit decision.
Finally, Udo Kock, deputy mayor of Amsterdam, noted that the city is committed to settling the EMA employees and their families quickly and making them feel at home. He believes that Amsterdam has already shown how serious this commitment is by actively helping EMA transition through the implementation of a specialized help desk.
“The relocation of EMA is very important to Amsterdam. This world-class institution with its highly specialized staff adds to Amsterdam’s international appeal as a place to live, to work, and to invest,” said Kock.
The press conference also included a viewing of the video that Amsterdam submitted to the EMA as part of its bid to host the regulatory body. In the presentation, Amsterdam touted its commitment to all EMA employees and their families by providing them with individual support and coaching to assist in finding housing and schools for their children. In order to maintain continuity and limit the effects of the move on the EMA, Amsterdam will provide a temporary headquarters until the custom building is ready for use. The new building will be within a 10-minute train ride to Schipol, Amsterdam’s international airport, and also in the proximity of many international and European schools.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
CMS Announces New Drug Prices Under the IRA, Including for Stelara and Enbrel
August 19th 2024CMS announced negotiated prices for 10 drugs under the Inflation Reduction Act (IRA), sparking mixed reactions, with concerns that including drugs facing imminent biosimilar competition could hinder market access to lower-cost alternatives.
The Subcutaneous Revolution: Zymfentra and the Future of IBD Care With Dr Andres Yarur
December 17th 2023On this episode of Not So Different, Andres Yarur, MD, a researcher and associate professor of medicine at Cedars-Sinai Medical Center, discusses the significance of the FDA approval for Zymfentra, the world's first subcutaneous infliximab product, for patients with inflammatory bowel disease (IBD).